The National Institutes of Health, through its All of Us Research Program, announced in January 2023 research funding opportunities to expand the use of the program’s data to advance precision medicine. NIH allocated up to $4.75 million in fiscal year 2023 for the research grants.

To address and achieve equity in health care, in fall 2022 the National Institute of Nursing Research (NINR) began offering new funding opportunities for research studies aligned with the scientific framework outlined in the institute’s 2022–2026 strategic plan. The grants are available cyclically with three application periods per year.

The National Institute of Nursing Research, an National Institutes of Health agency, released its 2022–2026 strategic plan in summer 2022 to support its mission of leading “nursing research to solve pressing health challenges and inform practice and policy—optimizing health and advancing health equity into the future.”

Healthcare organizations advocated to improve diversity among clinical trials in a letter sent to U.S. Congress in May encouraging the government to take steps as the reauthorization of the Prescription Drug User Fee Act (PDUFA) approaches. The PDUFA allows the U.S. Food and Drug Administration to review and approve drugs, but the authorization is set to expire in September of 2022.

Driven by the reignited Cancer Moonshot, the National Cancer Institute (NCI) hosted a virtual roundtable discussion on the possibilities and challenges of increasing clinical trial accrual in May 2022.  

Driving “cancer research that spans the continuum from basic science to survivorship” and taking advantage of the “incredible opportunity to greatly reduce the impact of cancer on people’s lives and end cancer as we know it” takes an investment, the National Cancer Institute (NCI) acknowledged in its proposed budget for the 2023 fiscal year. However, fully funding “cutting-edge research, infrastructure, and training needed to harness these opportunities allows researchers better understand how to prevent and treat cancer.”

Where there’s cancer, there are oncology nurses. It’s been that way even before 1971, when President Richard Nixon established and signed into law the National Cancer Act to fight the “war on cancer,” which had just become the second leading cause of death in the United States. Born from the act, the National Cancer Institute (NCI) celebrates its 50th anniversary in 2021. As part of the celebration, it named three oncology nurses and ONS members on its champions and changemakers list—Betty Ferrell, PhD, FAAN, FPCN, CHPN, Deborah Watkins Bruner, RN, PhD, FAAN, and Christine Miaskowski, RN, PhD, FAAN—in recognition of their contributions to cancer prevention, early detection, and symptom science.

Research has identified an association between malnutrition and functional deficits in patients with cancer, regardless of age, and other studies confirm that malnutrition affects treatment tolerability, outcomes, and quality of life for patients with cancer. However, studies have also found that oncology clinicians do not consistently assess for malnutrition and functional deficits in clinical settings. 

When the U.S. Congress passed the FY 2021 funding bill at the end of 2020, it recommitted its dedication to cancer research by increasing the National Institutes of Health’s National Cancer Institute’s (NCI’s) budget by $120 million.

During his final State of the Union address in January 2016, former President Barack Obama appointed Joe Biden the lead on a new initiative: the National Cancer Moonshot. The goal was to find treatments, cures, and more understanding about cancer—a decade’s worth of progress in just five years. 

In February 2019, my colleagues and I published a retrospective analysis of patient-reported satisfaction comparing those who had contact with an oncology nurse navigator (ONN) and those who did not. We analyzed surveys from patients with outpatient oncology infusion or radiation oncology visits in a 24-month period. First, we sorted the surveys into two groups—self-reported ONN contact (n = 315) and self-reported no contact with an ONN (n = 172)—and compared satisfaction.

What does the future of nursing research mean to you? How can nurse scientist-led studies provide information you can use in your daily practice? What gaps do you see in evidence to support nursing care?

Participation in clinician and patient conversations about lung cancer screening—as well as the actual screening itself—is relatively low. According to one study, only 3.9% of screening-
eligible patients had undergone lung cancer screening. Because the screening recommendations are newer, most patients are unaware that they exist, and research highlights that only 10%–12% of the patient population has had conversations with their clinicians about it.

Issues pertaining to geography, socioeconomic status, or racial or ethnic background can prohibit patients from accessing the treatment and care they need to successfully navigate their cancer diagnosis. Connecting patients to healthcare professionals and tailored interventions that educate, motivate, and reduce barriers can be a tremendous boon for their care and ultimately their outcomes.

Since the National Academies of Medicine (formerly the Institute of Medicine) issued Cancer Patient to Cancer Survivor: Lost in Transition in 2005, the oncology field has made small strides to implement successful survivorship resources to support patients after their treatment. Because of the vast differences in patient populations, disease types, study locations, and institutional resources, best practices to support patients transitioning from treatment to survivorship care are often unclear. This poses an issue for providers, and patients hear mixed messaging or little information for follow-up care. With many patients receiving treatment in outpatient settings, ambulatory oncology nurses must understand how to provide support for patients during their transition.

ONS member Ruth McCorkle, PhD, RN, FAPOS, FAAN, had a storied, trailblazing career in oncology nursing, leading the way to advance nursing research, patient-centered care, and educational excellence. McCorkle passed away on August 17, 2019, surrounded by her close family, leaving behind an indelible legacy to the oncology nursing profession.        

The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

Advanced practice RNs (APRNs), especially those with Doctorate of Nursing Practice degrees, in clinics across the country must not only focus on managing care for patients on novel therapies like immunotherapy but must also look at toxicities and adverse events from a population perspective. APRNs should look across all patients and disease types receiving the same novel treatments and recognize toxicity patterns to determine best practices for patient management. 

Still a popular program throughout the government, the Cancer Moonshot Initiative challenged the United States to meet goals to accelerate cancer research progress, encourage collaboration in finding treatments and cures, and to improve data sharing to make a decade’s progress in half the time. Through NIH’s Moonshot Blue Ribbon Panel and the 2016 passage of the 21st Century Cures Act—allocating $1.8 billion over seven years for Moonshot—the initiative is moving out of planning and into the research phase.

Recognizing the national opioid epidemic in the United States, the National Institutes of Health (NIH) has allocated a new funding stream for new research to address public health issues like prescription drug abuse and overdose. Through the Helping to End Addiction Long-Term (HEAL) Initiative, the NIH is offering 30 funding opportunities for researchers, awarding $850 million in support.

 The World Health Organization indicated that tobacco use is the most preventable cause of cancer worldwide. Globally, more than 7 million people die each year from causes associated with tobacco use and tobacco-related diseases. Despite recent trends that show falling rates for U.S.-based smokers, much work still must be done. Oncology nurses around the world can make a difference by engaging in prevention and treatment tactics, working with policymakers, and educating their communities and patients about tobacco control. 

The field of telehealth encompasses many efforts in oncology practice and research. When focusing specifically on telephone triage, we examine patient-initiated requests, such as speaking directly with their nurses on the phone, reporting side effects, or seeking answers to questions about plan of care and treatment. This provides oncology nurses with an opportunity for assessment and intervention. Although many current research efforts focus on proactive phone calls nurses make to their patients, it is also important to understand the impact of incoming calls on patient care and workflow.

Building on a long career as a pioneer in oncology nursing research and cancer clinical trials, ONS member Deborah Watkins Bruner, RN, PhD, FAAN, has been named the senior vice president of research at Emory University in Atlanta, GA, a newly created position that serves on the Emory president’s leadership team. Effective October 1, 2018, Bruner’s leadership, expertise, and research experience will guide Emory’s interprofessional research efforts and promote education and training for future researchers, including nurse scientists.

In 2016, the American Cancer Society (ACS) reported that the number of currently living cancer survivors is estimated at 15.5 million Americans. For 2018, ACS is projecting another 1.7 million new cases of cancer diagnoses. On one hand, the growing number of survivors indicates that early diagnosis, new technologies, targeted interventions, treatment options, and access to care are making a huge difference for patients. 

Patricia Grady, RN, PhD, FAAN, has defined a generation of nurse science and patient-centered research, serving as the National Institute of Nursing Research (NINR) director for more than 23 years. Under her charge, NINR has grown into one of the foremost federal agencies supporting the scope of the nursing research community, driving groundbreaking initiatives and furthering clinical practice.

Radiation therapy can be an incredibly draining form of treatment for patients with cancer. Side effects such as fatigue can be debilitating for many before, during, and after treatment. Because symptom management is a crucial component to cancer care and central role of oncology nursing, ensuring that patients are able to mitigate their symptoms and side effects can help improve their quality of life. Recently, a team at the National Institute of Nursing Research (NINR) identified certain genes associated with fatigue in men being treated for prostate cancer.

Long-time ONS member and oncology nurse scientist Karen Meneses, PhD, RN, FAAN, Professor and Associate Dean for Research at the School of Nursing at the University of Alabama at Birmingham (UAB) passed away unexpectedly on August 1, 2018.

Nurses can do it all. After all, the often-unsung heroes of health care use their unique skills to positively impact patients and their families in more ways than most people can ever imagine. Unfortunately, role confusion and a lack of awareness of a vital specialty have led to a dire need of nurses in clinical trials.

Whether being called on to inform the National Cancer Moonshot Initiative, develop novel resources for patients with prostate cancer, or create programs for smoking cessation, nurse scientists are continually advancing patient-centered oncology care. Nurse researcher contributions have led to improved patient outcomes, better symptom management interventions, and overall quality of care. As part of its commitment to future nursing research, ONS created a new scholar-in-residence position to drive and inform the Society’s research agenda and highlight the integral work of ONS member nurse scientists who are moving the needle for patients with cancer.

Nursing interventions such as coaching, telephone follow-up, and home care have been reported with inconsistent results. In their article in the January 2018 issue of the Oncology Nursing Forum, Coolbrandt et al. discussed the evaluation of a nursing intervention focused on patient education and self-management to reduce symptom distress in outpatients with cancer.

Twenty-five years ago, you could be flying at 39,000 feet and still be inhaling cigarette smoke. Smoking’s pervasiveness in U.S. culture was far and wide, and it wasn’t until cancer research findings—coupled with public policy and healthcare education—that the dangers of smoking caught on with the general public. Since then, smoking rates have declined.

Summer 2017 saw several attempts to repeal and replace the Affordable Care Act (ACA), none of which were successful. Now that the dust has started to settle—and Congress is slowly moving on to other issues—many are still dealing with the uncertainty left in the wake of the nation’s healthcare debate. This includes many concerned governors who are lobbying for funds to address their states’ current needs.

To ensure that future cancer research is of the highest quality, the National Cancer Institute (NCI) is committed to developing the best scientific minds. NCI training and funding opportunities cover a broad spectrum of disciplines for individuals at various stages in their careers, ranging from high school and graduate students to scientists, clinicians, and healthcare professionals. 

One of the key factors to a cancer clinical trial’s success is the ability to enroll an adequate number of patients in an appropriate timeframe. Identifying barriers to slow accrual and ways to address them can help researchers and nurse scientists make big steps in the fight against cancer in the era of the National Cancer Moonshot Initiative.